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Abstract 
Background: Daidzein is an isoflavone derived from soybeans that exerts preventive effects on bone loss in ovariec‑
tomized (OVX) animals. These effects have been correlated with increasing serum equol levels. In the present study, 
we investigated the effects of antibiotic intake on equol metabolism from daidzein, and the corresponding levels of 
bone loss in OVX mice.
Methods: Eight‑week‑old female ddY mice (n = 42) were either ovariectomized (OVX) or subjected to a sham opera‑
tion (sham). OVX mice were then divided into six dietary subgroups: control diet (control), 0.3 % kanamycin diet (KN), 
0.1 % daidzein diet (Dz), 0.1 % daidzein and 0.0375 % kanamycin diet (Dz+KN3.75), 0.1 % daidzein and 0.075 % kana‑
mycin diet (Dz+KN7.5), and 0.1 % daidzein and 0.3 % kanamycin diet (Dz+KN30). The mice were fed their respective 
diets for 4 weeks.
Results: Uterine weight and femoral bone mineral density (BMD) were significantly lower in the OVX mice compared 
in the sham mice. No significant differences in uterine weight were observed among all OVX dietary subgroups. The 
Dz subgroup was found to exhibit higher plasma equol and O‑desmethylangolensin (O‑DMA) concentrations, as well 
as greater femoral BMD, compared to all other OVX subgroups. Furthermore, when compared to the Dz group, kana‑
mycin intake decreased plasma equol and O‑DMA concentrations, as well as femoral BMD in the OVX mice.
Conclusions: These results suggest that kanamycin intake inhibited the conversion of daidzein to equol and O‑DMA, 
blocking the preventive effects of daidzein on bone loss in OVX mice. Therefore, the bone‑protective effects of daid‑
zein intake may be predominantly associated with increased plasma concentrations of either equol or O‑DMA.
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Background
Soybean isoflavones have molecular structures that are 
similar to estrogen, and exhibit a weak affinity for estro-
gen receptors [1]. Previous studies have demonstrated 
that soybean isoflavones prevent bone loss in ovariecto-
mized (OVX) animals [2–6]. However, some intervention 
trials found positive effects of soy and soy isoflavones 
specifically on bone mineral density (BMD) and/or bio-
markers of bone metabolism in pre- and postmenopausal 
women [7–9], whereas others have reported no signifi-
cant effects or effects without clinical relevance [10, 11]. 
Because all subjects received minerals and vitamins such 
as calcium and vitamin D in clinical trials of Caucasian 
women, the effects of isoflavones on the bone remain 
unclear. This may explain the controversial results of var-
ious studies. Additionally, isoflavone metabolites can be 
produced, particularly equol from daidzein.
Daidzein is one of the predominant soybean isofla-
vones, and it is metabolized by gut microflora in the 
gastrointestinal tract to form equol or O-desmethyl-
angolensin (O-DMA). Of these two metabolites, equol 
exhibits stronger estrogenic activity than daidzein [12]. 
We previously reported that soybean isoflavone intake 
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increased plasma equol concentration, and inhibited 
bone loss in OVX mice, whereas fructooligosaccharides 
were found to stimulate the gut microflora leading to 
increased genistein, daidzein, and equol bioavailability 
[13, 14]. Furthermore, we reported that equol directly 
inhibited bone loss in OVX mice [15]. In a human study, 
we performed a 1-year double-blind randomized trial to 
compare the effects of isoflavone (75  mg of isoflavone 
conjugates/day) with those of placebo on BMD, fat mass, 
and serum isoflavone concentrations in early postmeno-
pausal Japanese women who were classified based on 
their equol-producer phenotype [16]. Significant differ-
ences were observed between the equol producers and 
nonproducers in the isoflavone group with regard to the 
annualized changes in BMD and fat mass [16]. Therefore, 
it has been suggested that equol derived from daidzein 
may have a bone-protective effect.
Recent studies have suggested that the clinical effec-
tiveness of isoflavones may depend on the ability of 
an individual to produce equol [12, 16–18]. Although 
only 30–50  % of the human population can produce 
equol [18–20], common laboratory animals consistently 
produce high levels of equol. Therefore, the daidzein-
induced bone-protective effect cannot be evaluated in 
the presence of this innate equol production. Previous 
investigators have reported that kanamycin antibiotic 
treatment resulted in a marked reduction in plasma 
equol concentration in cynomolgus monkeys [21]. In the 
present study, we investigated the effects of kanamycin 
antibiotic intake on daidzein-derived equol production 
and bone loss in OVX mice.
Methods
Experimental design
The Animal Study Committee of the National Institute of 
Health and Nutrition approved this study. All procedures 
were undertaken in accordance with the Committee of 
the National Institute of Health and Nutrition Guide-
lines for the Care and Use of Laboratory Animals. Eight-
week-old female ddY mice (n  =  42) were purchased 
from Japan SLC, Inc. (Shizuoka, Japan) and individually 
cage-housed in a room maintained at 23  °C with a 12-h 
light/dark cycle. Mice received a sham operation (sham) 
or were OVX. Sham mice were fed a control diet based 
on the AIN-93G formulation described previously [22], 
but containing corn oil rather than soybean oil. OVX 
mice were divided into six dietary subgroups: control 
diet (control), 0.3 % kanamycin diet (KN), 0.1 % daidzein 
diet (Dz), 0.1  % daidzein and 0.0375  % kanamycin diet 
(Dz+KN3.75), 0.1  % daidzein and 0.075  % kanamycin 
diet (Dz+KN7.5), and 0.1 % daidzein and 0.3 % kanamy-
cin diet (Dz+KN30). We chose kanamycin doses in the 
respective diets based on an experiment of cynomolgus 
monkeys [21]. The mice were fed their respective diets 
and allowed deionized water ad  libitum throughout the 
study period. Animals were weighed by electronic bal-
ance at 10:00 in every week. After 4  weeks, the mice 
were euthanized by examination under anesthetized with 
pentobarbital sodium (40  mg/kg body weight) and sac-
rificed. Blood, uterine tissue, and femoral bone samples 
were collected for analysis.
Radiographic analysis of the femur
Radiographic analysis of the right femur was performed 
using a soft X-ray system. The left femur was removed 
and stored in 70  % ethanol at 4  °C and dried at 60  °C 
overnight before analysis. Femoral bone mineral content 
(BMC) and BMD were measured by dual-energy X-ray 
absorptiometry (DXA) using the DCS-600EX-R system 
(Hitachi Aloka Medical, Ltd., Tokyo, Japan). BMD was 
calculated using BMC of the measured area. Intra-assay 
and Inter-assay coefficients of variation were less than 1.0 
and 4.8 %, respectively. The detection limit of BMD was 
15 mg/cm2. The mineralization profiles of the femur were 
stored from the monitor images, and the BMC and BMD 
values were obtained for the femur.
Time‑resolved fluoroimmunoassay (TR‑FIA) for plasma 
daidzein, equol, and O‑desmethylangolensin (O‑DMA)
A TR-FIA was utilized to determine plasma levels of 
daidzein, equol, and O-DMA as described by Wang 
et al. [23], Brouwers et al. [24], and L’homme et al. [25], 
respectively. This volume corresponded to 20  μL of the 
original plasma sample. Samples showing a value outside 
the range of the standard curve were diluted with assay 
buffer. Another 20 μL of the solution was used for liquid 
scintillation counting to determine recovery. Based on 
these results, the final values were corrected for losses 
during hydrolysis and extraction. Before the assay, micro-
strips coated with goat anti-rabbit immunoglobulin G 
were prewashed using 1296–026 DELFIA platewash 
(Wallac, Oy Turku, Finland). A volume of 20  μL of the 
standard or hydrolysed and extracted plasma samples 
was pipetted onto the microstrips, then 100  μL of anti-
serum in 50 mM Tris–HCl buffer containing 5 g/L BSA 
(pH 7.8) for daidzein, equol, or O-DMA and 100  μL of 
europium-labelled daidzein, equol, or O-DMA was added 
per well. The strips were placed on a 1296–003 DELFIA 
shaker (Wallac) and shaken slowly at room tempera-
ture for 90 min, and then washed in the DELFIA plate-
washer (Wallac) using the no. 29-T3 program. A volume 
of 200  μL of DELFIA enhancement solution 1244–105 
(PerkinElmer, Weltham, MA, USA) was added to each 
well, and the strips were shaken slowly for an additional 
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5  min. Fluorescence was read using the DELFIA Victor 
1420 multi-label counter (Wallac) and the accompany-
ing software (version 1.0) for data analysis. The final con-
centrations (Concs) were calculated using the following 
formula:
The average percent coefficient of variation (% CV) val-
ues for the daidzein, equol, and O-DMA assays are 4.0, 
5.5, and 5.6 %, respectively [23–25].
Statistical analysis
Data were expressed as the mean ± SEM. After perform-
ing a one-way analysis of variance, the statistical signifi-
cance of any differences was determined using Fisher’s 
protected least significant difference test (StatView 4.0, 
Abacus Concepts, Piscaraway, NJ, USA). P values less 
than 0.05 were considered significant. Bars not sharing 
letters denote significant differences in figures.
Results
Body and uterine weight
Initial body weight did not differ among the groups. 
The final body weight was significantly higher (P < 0.05) 
in the OVX control group than in the sham group and 
other five OVX subgroups, but there were no significant 
differences among the sham and other five groups (data 
not shown). Uterine weight was significantly decreased 
by ovariectomy (P < 0.05), indicating that the mice were 
estrogen-deficient. Additionally, daidzein with or without 
kanamycin intake did not affect uterine weight (Fig. 1).
Conc = Conc (read) × (1/recovery factor)
× dilution factor (nmol/l)
BMC and BMD of the femur
As shown by the radiography results, daidzein inhibited 
bone loss in the femur in OVX mice, while simultane-
ous intake of kanamycin did not rescue this bone loss 
(Fig.  2A). Femoral BMC was significantly lower in the 
OVX group than in the sham group (Fig. 2B). BMC of the 
femur in the OVX Dz subgroup was significantly higher 
than in the other OVX subgroups (P  <  0.05), and there 
were no significant differences among the control, KN, 
Dz+KN3.75, Dz+KN7.5, and Dz+KN30 subgroups. In 
mice fed the daidzein-supplemented diets, femoral BMC 
was significantly lower in the kanamycin-treated groups 
(KN, Dz+KN3.75, Dz+KN7.5, and Dz+KN30) than in 
the Dz group (P < 0.05) (Fig. 2B). A similar tendency was 
observed for BMD (Fig. 2C).
Plasma daidzein, equol, and O‑DMA concentrations
Daidzein intake increased plasma daidzein, equol, and 
O-DMA concentrations in OVX mice (Fig. 3A–C). In the 
mice receiving daidzein-supplemented diets, kanamycin 
intake did not alter plasma daidzein concentration, but 
plasma equol and O-DMA concentrations decreased.
Discussion
A previous study showed that daidzein prevented BMD 
decreases in the femur and the lumbar vertebrae of OVX 
rats without evidence of uterine hypertrophy [26]. In the 
present study, uterine weight as well as femoral BMC and 
BMD were significantly lower in the OVX group than in 
the sham group. Furthermore, daidzein intake inhibited 
BMC and BMD decreases in the femur, but had no signif-
icant effect on uterine weight in OVX mice. Isoflavones 
are candidate chemicals as selective estrogen recep-
tor modulators (SERMs). SERMs are estrogen receptor 
ligands that act as estrogen on the bone, while blocking 
estrogen action in reproductive organs [27]. Although 
high isoflavone doses have been shown to induce uterine 
hypertrophy in OVX mice [3], the results of the present 
study suggest that appropriate daidzein intake improved 
BMC and BMD without uterine hypertrophy. The femo-
ral radiographic images obtained using a soft X-ray sys-
tem corroborated these findings (Fig. 2A).
Microflora in the gastrointestinal tract metabolize 
daidzein to produce equol or O-DMA [12, 19, 28]. Mice 
have an innate ability to produce equol [12], and there-
fore equol production was inhibited in some of the mice 
subgroups in this study by kanamycin antibiotic treat-
ment. Kanamycin treatment has been shown to cause 
a marked reduction in plasma equol concentrations in 
cynomolgus monkeys [21]. Furthermore, Bowey et  al. 































Fig. 1 Uterine weight. The data are presented as the mean ± SEM for 
each group of 6 mice. a, b Bars not a sharing letters denote significant 
differences (P < 0.05)
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urine from germ-free rats [28]. In the present study, kan-
amycin treatment did not change the plasma daidzein 
concentration, but it did decrease plasma concentrations 
of equol and O-DMA in mice fed daidzein-supplemented 
diets. These results suggest that kanamycin intake inter-
feres with the conversion of daidzein to equol and O-
DMA in the gastrointestinal tract without alterating 
daidzein absorption.
In the present study, daidzein intake increased plasma 
concentrations of daidzein, equol, and O-DMA in OVX 
mice. In addition, femoral BMC and BMD were signifi-
cantly higher in the Dz group than in the control group. 
We previously showed that equol prevented a reduction 
in femoral bone loss in OVX mice [15]. Furthermore, O-
DMA exhibits an inhibitory effect on in vitro osteoclast 
formation [29]. Therefore, it is not possible to assess the 
daidzein-induced bone-protective effect in the presence 
of metabolites such as equol and O-DMA. Because kana-
mycin reduces the population of equol-producing bacte-
ria, the metabolism of equol and O-DMA from daidzein 
may be inhibited during enterohepatic recirculation. Fur-
thermore, bone loss was also observed in the kanamycin-
treated OVX subgroups (KN, Dz+KN3.75, Dz+KN7.5, 
and Dz+KN30) despite daidzein supplementation. These 
results suggest that daidzein intake combined with kana-
mycin treatment does not inhibit reductions in femoral 
BMC and BMD in OVX mice. Thus, the bone-protec-
tive effects of daidzein intake may be primarily affected 
by either the equol or O-DMA metabolite. Based on 
the results of our previous study [29], equol may exert a 
greater effect on bone than does O-DMA. Taken together 
with the present study, equol may be the most effective 
compound in bone among the three isoflavonoids.
Conclusions
In the present study, we utilized an OVX model in mice 
to demonstrate the effects of kanamycin antibiotic intake 
on equol metabolized from daidzein, and the impact 
on bone loss. Kanamycin intake inhibited increases in 
plasma equol and O-DMA concentrations, and femoral 
OVX
Dz
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Fig. 2 Radiography (A), BMC (B), and BMD (C) of the femur. The data are presented as the mean ± SEM for each group of 6 mice. a–c Bars not shar‑
ing letters denote significant differences (P < 0.05)
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BMC and BMD decreased in the kanamycin-treated 
OVX subgroups despite dietary supplementation with 
daidzein. These results suggest that either equol or O-
DMA may is a key factor related to the bone-protective 
effects of daidzein.
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